Bhavesh Shah, RPh, BCOP

Closing out their discussion on cardiovascular disease in prostate cancer, experts share their hopes for future evolution of the treatment landscape.

Shared insight on the value of multidisciplinary care and its current state in cardiovascular disease and prostate cancer.

Maria Lopes, MD, MS, elucidates the potential for quality measures and coverage policies to incorporate cardiovascular disease (CVD) and improve outcomes in prostate cancer.

Experts share insight on the need for clinical or real-world evidence to further solidify cardiovascular disease risk as an actionable factor in prostate cancer.

Expert perspectives on factors that inform prostate cancer therapy selection while keeping cardiovascular disease in mind.

Continuing their discussion on cost of care in prostate cancer, experts reflect on how cardiovascular disease impacts risk-bearing practices and alternative payment models.

Shared insight on the impact that cardiovascular disease has on cost of care in prostate cancer.

Experts consider available professional society guidelines on prostate cancer and cardiovascular disease management.

A brief review of factors that may put patients with prostate cancer at increased risk for developing cardiovascular disease.

Focusing on available agents in prostate cancer, experts consider how androgen deprivation therapy impacts risk of cardiovascular disease.

A comprehensive review of the therapeutic classes available for patients with prostate cancer.

Shared insight on the correlation between prostate cancer and cardiovascular disease, with a focus on the attributes that increase a patient’s risk.

A broad look at the economic burden of prostate cancer and outlook in regard to survival within the current treatment landscape.

Expert perspectives on prostate cancer with deference to clinical presentations, diagnosis, and prognosis.